Leyden Labs
Leyden Labs develops a Mucosal Protection Platform to protect against respiratory viruses, including influenza and coronaviruses. The company offers a portfolio of broad protective nasal sprays designed to reduce the risk of infection and limit transmission, aiming to improve public health through innovative protection methods. Its team combines biotechnology veterans with new talent to advance solutions that address common viral threats at the mucosal surface.
1 past transactions
CoV Biotechnology
Acquisition in 2025
CoV Biotechnology is an early-stage biotechnology company dedicated to addressing the challenges posed by the evolving and mutating nature of coronaviruses. The company develops booster vaccines and therapeutics specifically designed to combat variants of the SARS-2 beta coronavirus. By focusing on creating vaccines that offer broad-spectrum protection against both current and future variants, as well as potential zoonotic crossovers from animals to humans, CoV Biotechnology aims to provide effective solutions to enhance immunity and reduce the impact of future coronavirus pandemics.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.